Trial Profile

Efficacy, Safety, and Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 Infection

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
Indications HIV-1 infections
Focus Therapeutic Use

Most Recent Events

08 Oct 2020 Results assessing secondary analysis to determine any associations with PROs and weight change at Week 48 after switching from EFV/FTC/TDF to BIC/FTC/TAF, presented at the 15th International Congress on Drug Therapy and HIV Infection.
17 Jan 2020 Status changed from active, no longer recruiting to completed.
13 Aug 2019 Planned primary completion date changed from 20 Jun 2019 to 30 Nov 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com